Advanced

Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: An observational study

Fernstrom, Anders; Giaever, Jan; Granroth, Barbara; Hylander, Britta; Jensen, Gert; Christensson, Anders LU ; Wikstrom, Bjorn; Weiss, Lars; Wrege, Ulf and Jacobson, Stefan H. (2011) In Scandinavian Journal of Urology and Nephrology1967-01-01+01:002013-01-01+01:00 45(3). p.196-205
Abstract
Objective. Secondary hyperparathyroidism (SHPT) is a common problem among patients with chronic kidney disease (CKD) on haemodialysis. This study was conducted to assess the use, effectiveness and safety of intravenous paricalcitol in haemodialysis patients with various degrees of SHPT. Material and methods. This observational, multicentre, prospective study was conducted in 14 Swedish dialysis centres from May 2007 to June 2008 and included 92 haemodialysis patients with a diagnosis of SHPT associated with CKD. The decision to initiate treatment with intravenous paricalcitol was made by the treating physician. No treatment algorithms were provided. Results. Mean patient age was 64 years. Of the 92 patients included, 74 had an intact... (More)
Objective. Secondary hyperparathyroidism (SHPT) is a common problem among patients with chronic kidney disease (CKD) on haemodialysis. This study was conducted to assess the use, effectiveness and safety of intravenous paricalcitol in haemodialysis patients with various degrees of SHPT. Material and methods. This observational, multicentre, prospective study was conducted in 14 Swedish dialysis centres from May 2007 to June 2008 and included 92 haemodialysis patients with a diagnosis of SHPT associated with CKD. The decision to initiate treatment with intravenous paricalcitol was made by the treating physician. No treatment algorithms were provided. Results. Mean patient age was 64 years. Of the 92 patients included, 74 had an intact parathyroid hormone (iPTH) level of > 300 pg/ml at baseline. Median iPTH was 584 pg/ml in patients with a baseline PTH of > 300 pg/ml. During follow-up there was a decrease in iPTH to 323 pg/ml at 6 months (--45%, p < 0.0001). In parallel, there was a small increase in serum calcium, but serum phosphorus and the calcium xx phosphorus product remained unchanged. Conclusions. This study showed that intravenous paricalcitol substantially and safely decreased iPTH in haemodialysis patients with a baseline iPTH above the Kidney Disease Outcomes Quality Initiative recommended target range (150--300 pg/ml) and had minimal impact on serum minerals. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Dose titration, paricalcitol, SHPT
in
Scandinavian Journal of Urology and Nephrology1967-01-01+01:002013-01-01+01:00
volume
45
issue
3
pages
196 - 205
publisher
Taylor & Francis
external identifiers
  • wos:000288379800006
  • scopus:79952758440
ISSN
0036-5599
DOI
10.3109/00365599.2011.553738
language
English
LU publication?
yes
id
6a878f3b-7548-4680-ab46-3c03cf19ca6f (old id 1926405)
date added to LUP
2011-05-02 08:23:29
date last changed
2017-09-10 04:22:35
@article{6a878f3b-7548-4680-ab46-3c03cf19ca6f,
  abstract     = {Objective. Secondary hyperparathyroidism (SHPT) is a common problem among patients with chronic kidney disease (CKD) on haemodialysis. This study was conducted to assess the use, effectiveness and safety of intravenous paricalcitol in haemodialysis patients with various degrees of SHPT. Material and methods. This observational, multicentre, prospective study was conducted in 14 Swedish dialysis centres from May 2007 to June 2008 and included 92 haemodialysis patients with a diagnosis of SHPT associated with CKD. The decision to initiate treatment with intravenous paricalcitol was made by the treating physician. No treatment algorithms were provided. Results. Mean patient age was 64 years. Of the 92 patients included, 74 had an intact parathyroid hormone (iPTH) level of &gt; 300 pg/ml at baseline. Median iPTH was 584 pg/ml in patients with a baseline PTH of &gt; 300 pg/ml. During follow-up there was a decrease in iPTH to 323 pg/ml at 6 months (--45%, p &lt; 0.0001). In parallel, there was a small increase in serum calcium, but serum phosphorus and the calcium xx phosphorus product remained unchanged. Conclusions. This study showed that intravenous paricalcitol substantially and safely decreased iPTH in haemodialysis patients with a baseline iPTH above the Kidney Disease Outcomes Quality Initiative recommended target range (150--300 pg/ml) and had minimal impact on serum minerals.},
  author       = {Fernstrom, Anders and Giaever, Jan and Granroth, Barbara and Hylander, Britta and Jensen, Gert and Christensson, Anders and Wikstrom, Bjorn and Weiss, Lars and Wrege, Ulf and Jacobson, Stefan H.},
  issn         = {0036-5599},
  keyword      = {Dose titration,paricalcitol,SHPT},
  language     = {eng},
  number       = {3},
  pages        = {196--205},
  publisher    = {Taylor & Francis},
  series       = {Scandinavian Journal of Urology and Nephrology1967-01-01+01:002013-01-01+01:00},
  title        = {Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: An observational study},
  url          = {http://dx.doi.org/10.3109/00365599.2011.553738},
  volume       = {45},
  year         = {2011},
}